Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pancreatic peptide hold clues to PCOS-Related insulin resistance?

NCT ID NCT07736079

Knowledge-focused Sponsor: GÜLDEN ANATACA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looks at whether a hormone called preptin, which is released alongside insulin, is linked to insulin resistance in women with polycystic ovary syndrome (PCOS). Researchers will measure preptin levels in 60 women diagnosed with PCOS and compare them to markers of insulin resistance. The goal is to better understand the metabolic problems that often accompany PCOS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If preptin is linked to insulin resistance in PCOS, it could point toward a new target for diagnosis or treatment.
What could go wrong
This is a small observational study, so it can only show a connection, not prove cause and effect. Results may not apply to all women with PCOS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This single-center prospective comparative cross-sectional study will include reproductive-aged women between 18 and 45 years of age who present to the Internal Medicine outpatient clinic with complaints of hirsutism, menstrual irregularity, and hyperandrogenism between June 15, 2026 and September 15, 2026. Participants diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria will constitute the PCOS group. The control group will consist of women with similar clinical complaints who do not meet the Rotterdam diagnostic criteria for PCOS. Only non-obese women with a body mass index (BMI) below 30 kg/m² will be included. Participants with pregnancy, breastfeeding, active infection, chronic systemic disease, rheumatologic or inflammatory disease, diabetes mellitus, hypertension, chronic renal failure, or those receiving treatment for PCOS within the last 6 months will be excluded. All participants will provide written informed consent before enrollment.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18-45 years * Diagnosis of PCOS according to Rotterdam criteria * BMI \<30 kg/m² * No PCOS treatment during the previous 6 months * Not pregnant or breastfeeding * No active infection * No rheumatologic or inflammatory disease * No chronic systemic disease * Written informed consent Exclusion Criteria: * Age \<18 years or \>45 years * Pregnancy or breastfeeding * PCOS treatment within the previous 6 months * Active infection * Rheumatologic or inflammatory disease * Hypertension * Diabetes mellitus * Chronic kidney disease * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperandrogenism Insulin Resistance polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Polycystic ovary syndrome (PCOS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.